Table 4.
Factor-specific incidences of adverse reactions to high-dose IVIG*.
| Patient basis (n=388) | Infusion basis (n=2888) | |||||||
|---|---|---|---|---|---|---|---|---|
| Adverse reaction | Adverse reaction | |||||||
| No | Yes | p value | No | Yes | p value | |||
| Gender, n (%) | ||||||||
| Male | 169 (96.0) | 7 (4.0) | 961 (98.6) | 14 (1.4) | ||||
| Female | 186 (87.7) | 26 (12.3) | 0.003 | 1820 (95.6) | 83 (4.4) | < 0.001 | ||
| Age, n (%) | ||||||||
| < 15 years | 196 (99.0) | 2 (1.0) | 314 (99.4) | 2 (0.6) | ||||
| ≥ 15 years | 159 (83.7) | 31 (16.3) | < 0.001 | 2467 (96.3) | 95 (3.7) | 0.003 | ||
| IVIG doses (average, g/kg BW) | 3.0† | 10.9† | 0.003 | 0.65 | 0.48 | 0.004 | ||
| Indication, n (%) | ||||||||
| Autoimmune | 344 (91.2) | 33 (8.8) | 2759 (96.6) | 97 (3.4) | ||||
| Neuromuscular | 52 (73.2) | 19 (26.8) | 973 (93.7) | 65 (6.3) | ||||
| Dermatologic | 51 (87.9) | 7 (12.1) | 1078 (97.8) | 24 (2.2) | ||||
| ITP | 59 (96.7) | 2 (3.3) | 339 (99.4) | 2 (0.6) | ||||
| EGPA | 13 (81.2) | 3 (18.8) | 149 (97.4) | 4 (2.6) | ||||
| Kawasaki disease | 169 (98.8) | 2 (1.2) | 220 (99.1) | 2 (0.9) | ||||
| Others | 11 (100.0) | 0 (0.0) | 22 (100.0) | 0 (0.0) | ||||
*The high-dose IVIG is more than 0.7 g/kg body weight per course.
†The values indicate the cumulative doses from multiple treatment of IVIG on one patient.
BW, body weight of patient.